Administration of mesenchymal stem cells (MSCs) to diseased hearts improves cardiac
function and reduces scar. These effects occur via stimulation of endogenous repair …

Basic experimental stem cell research has opened up the possibility of many diverse clinical
applications; however, translation to clinical trials has been restricted to only a few diseases …

Background: In addition to scalability, human embryonic stem cells (hESCs) have the unique
advantage of allowing their directed differentiation toward lineage-specific cells. Objectives …

A large number of clinical trials have shown stem cell therapy to be a promising therapeutic
approach for the treatment of cardiovascular diseases. Since the first transplantation into …

Aims Comparative studies suggest that stem cells committed to a cardiac lineage are more
effective for improving heart function than those featuring an extra-cardiac phenotype. We …

Induced pluripotent stem cells (iPSCs) are reprogrammed cells that have features similar to
embryonic stem cells, such as the capacity of self-renewal and differentiation into many …

Pluripotent stem cells (PSCs) hold great promise for drug discovery and regenerative
medicine owing to their ability to differentiate into any cell type in the body. After more than …

Despite improvements in modern cardiovascular therapy, the morbidity and mortality of
ischaemic heart disease (IHD) and heart failure (HF) remain significant in Europe and …

Rationale: Tissue engineering approaches may improve survival and functional benefits
from human embryonic stem cell–derived cardiomyocyte transplantation, thereby potentially …

For decades, mesenchymal stem (MSCs) cells have been used for cardiovascular diseases
as regenerative therapy. This review is an attempt to summarize the types of MSCs involved …